Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 10 full-time employees. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Purple Biotech Ltd 주요 수익원은 Base Rent - Fixed - Company Owned Property이며, 최신 수익 발표에서 수익은 13,107,528입니다. 지역별로는 United States이 Purple Biotech Ltd의 주요 시장이며, 수익은 21,593,264입니다.